Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LMNL Stock Summary
Top 10 Correlated ETFs
LMNL
In the News

Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.

Liminal BioSciences to Present at BIO CEO & Investor Conference
LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.

Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.

Liminal Biosciences to Present at Upcoming Investor Conferences
LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).

Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia. The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business
LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion").

Liminal BioSciences Announces Closing of Sale of Priority Review Voucher
LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Priority Review Voucher ("PRV") for USD 105 million.

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript

Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates
Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
LMNL Financial details
LMNL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 57.19 | 66.15 | 0.31 | 0.14 | 0.02 | |
Net income per share | -160.44 | -272.78 | -12.81 | -4.83 | 0.43 | |
Operating cash flow per share | -179.21 | -115.13 | -6.19 | -3.11 | -3.3 | |
Free cash flow per share | -193.95 | -122.29 | -6.46 | -3.19 | -3.32 | |
Cash per share | 33.87 | 10.32 | 3.82 | 1.84 | 3.6 | |
Book value per share | 178.35 | -79.03 | 6.36 | 0.95 | 1.41 | |
Tangible book value per share | -19.32 | -115.82 | 5.05 | -0.02 | 1.01 | |
Share holders equity per share | 178.35 | -79.03 | 6.36 | 0.95 | 1.41 | |
Interest debt per share | 147.19 | 217.63 | 3.81 | 3.38 | 2.22 | |
Market cap | 8.91B | 1.9B | 1.76B | 1.31B | 419.02M | |
Enterprise value | 8.98B | 2.03B | 1.74B | 1.34B | 371.31M | |
P/E ratio | -81.18 | -9.74 | -8.55 | -11.1 | 32.53 | |
Price to sales ratio | 227.74 | 40.16 | 358.47 | 394.55 | 651.66 | |
POCF ratio | -72.67 | -23.07 | -17.69 | -17.24 | -4.21 | |
PFCF ratio | -67.15 | -21.72 | -16.93 | -16.79 | -4.19 | |
P/B Ratio | 73.02 | -33.61 | 17.2 | 56.66 | 9.83 | |
PTB ratio | 73.02 | -33.61 | 17.2 | 56.66 | 9.83 | |
EV to sales | 229.51 | 42.82 | 355.57 | 403.27 | 577.47 | |
Enterprise value over EBITDA | -80.42 | -10.82 | -9.58 | -13.25 | 15.68 | |
EV to operating cash flow | -73.24 | -24.6 | -17.54 | -17.62 | -3.73 | |
EV to free cash flow | -67.67 | -23.16 | -16.79 | -17.16 | -3.71 | |
Earnings yield | -0.01 | -0.1 | -0.12 | -0.09 | 0.03 | |
Free cash flow yield | -0.01 | -0.05 | -0.06 | -0.06 | -0.24 | |
Debt to equity | 1.15 | -2.93 | 0.69 | 4.45 | 2.16 | |
Debt to assets | 0.49 | 1.61 | 0.42 | 0.87 | 0.73 | |
Net debt to EBITDA | -0.62 | -0.67 | 0.08 | -0.29 | -2.02 | |
Current ratio | 2.01 | 1.14 | 3.03 | 3.07 | 6.2 | |
Interest coverage | -14.9 | -5.09 | -8.41 | -10.79 | -7.84 | |
Income quality | 1.12 | 0.42 | 0.48 | 0.64 | -7.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 2.57 | 1.93 | 15.32 | 17.13 | 28.53 | |
Intangibles to total assets | 0.55 | 0.19 | 0.08 | 0.13 | 0.03 | |
Capex to operating cash flow | 0.08 | 0.06 | 0.04 | 0.03 | 0 | |
Capex to revenue | -0.26 | -0.11 | -0.91 | -0.62 | -0.72 | |
Capex to depreciation | -2.2 | -0.94 | -0.45 | -0.24 | -0.11 | |
Stock based compensation to revenue | 0.22 | 0.14 | 4.41 | 1.87 | 6.58 | |
Graham number | 802.38 | 696.47 | 42.82 | 10.13 | 3.69 | |
ROIC | -0.5 | -1.57 | -3.69 | -5.08 | 0.51 | |
Return on tangible assets | -0.86 | -2.35 | -1.36 | -1.15 | 0.11 | |
Graham Net | -133.13 | -192.2 | 0.3 | -2.05 | 0.57 | |
Working capital | 36.26M | 5.11M | 63.59M | 49.24M | 96.14M | |
Tangible asset value | -13.22M | -82.95M | 81.09M | -480K | 30.37M | |
Net current asset value | -68.17M | -125.2M | 24.69M | -29.75M | 22.46M | |
Invested capital | 0.76 | -2.36 | 0.46 | 3.2 | 1.43 | |
Average receivables | 9.87M | 15.46M | 16.64M | 8.6M | 2.49M | |
Average payables | 16.8M | 20.22M | 15.8M | 9.82M | 7.46M | |
Average inventory | 24.84M | 24.02M | 9.78M | 8.45M | 4.69M | |
Days sales outstanding | 102.23 | 153.88 | 989.91 | 429.48 | 606.25 | |
Days payables outstanding | 695.29 | 202.63 | 1.39K | 1.64K | 0 | |
Days of inventory on hand | 1.3K | 115.53 | 995 | 1.68K | 0 | |
Receivables turnover | 3.57 | 2.37 | 0.37 | 0.85 | 0.6 | |
Payables turnover | 0.52 | 1.8 | 0.26 | 0.22 | 0 | |
Inventory turnover | 0.28 | 3.16 | 0.37 | 0.22 | 0 | |
ROE | -0.9 | 3.45 | -2.01 | -5.11 | 0.3 | |
Capex per share | -14.74 | -7.16 | -0.28 | -0.08 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.01 | 0 | 0 | 0.01 | 0 | |
Net income per share | 2.74 | -0.21 | -0.34 | -0.19 | 0.71 | |
Operating cash flow per share | -1.91 | -0.16 | -0.23 | -0.22 | -0.38 | |
Free cash flow per share | -1.91 | -0.16 | -0.23 | -0.22 | -0.38 | |
Cash per share | 3.9 | 1.35 | 1.97 | 1.8 | 1.31 | |
Book value per share | 1.88 | 0.53 | 1.05 | 0.88 | 1.3 | |
Tangible book value per share | 1.46 | 0.38 | 0.75 | 0.57 | 1.3 | |
Share holders equity per share | 1.88 | 0.53 | 1.05 | 0.88 | 1.3 | |
Interest debt per share | 2.17 | 0.78 | 0.78 | 0.77 | 0.08 | |
Market cap | 871.74M | 1.12B | 384.24M | 203.41M | 178.29M | |
Enterprise value | 818.21M | 1.07B | 345.79M | 170.72M | 139.1M | |
P/E ratio | 2.65 | -16.43 | -9.06 | -8.57 | 2.03 | |
Price to sales ratio | 5.13K | 4.69K | 0 | 1.3K | 59.43K | |
POCF ratio | -15.25 | -87.27 | -54.54 | -30.01 | -15.24 | |
PFCF ratio | -15.22 | -87.22 | -54.54 | -29.97 | -15.24 | |
P/B Ratio | 15.46 | 26.18 | 11.76 | 7.46 | 4.41 | |
PTB ratio | 15.46 | 26.18 | 11.76 | 7.46 | 4.41 | |
EV to sales | 4.81K | 4.49K | 0 | 1.09K | 46.37K | |
Enterprise value over EBITDA | 9.64 | -73.76 | -37.42 | -35.62 | 6.01 | |
EV to operating cash flow | -14.31 | -83.54 | -49.08 | -25.19 | -11.89 | |
EV to free cash flow | -14.28 | -83.49 | -49.08 | -25.16 | -11.89 | |
Earnings yield | 0.09 | -0.02 | -0.03 | -0.03 | 0.12 | |
Free cash flow yield | -0.07 | -0.01 | -0.02 | -0.03 | -0.07 | |
Debt to equity | 1.77 | 2.16 | 1.65 | 1.95 | 0.33 | |
Debt to assets | 0.68 | 0.73 | 0.7 | 0.75 | 0.25 | |
Net debt to EBITDA | -0.63 | 3.29 | 4.16 | 6.82 | -1.69 | |
Current ratio | 6.21 | 6.2 | 2.77 | 2.35 | 4.85 | |
Interest coverage | -7.58 | -6.24 | -6.82 | -9.71 | -8.26 | |
Income quality | -0.7 | 0.75 | 0.66 | 1.14 | -0.53 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 29.6 | 1.46K | |
Research and developement to revenue | 29.25 | 19.07 | 0 | 25.11 | 1.17K | |
Intangibles to total assets | 0.03 | 0.03 | 0 | 0 | 0.06 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.76 | -0.03 | 0 | -0.05 | -1 | |
Capex to depreciation | -0.16 | -0.01 | 0 | -0.03 | -0.01 | |
Stock based compensation to revenue | 10.37 | 2.62 | 0 | 3.42 | 137.67 | |
Graham number | 10.78 | 1.59 | 2.84 | 1.94 | 4.55 | |
ROIC | 0.17 | 0.11 | 0.17 | 0.21 | 0.29 | |
Return on tangible assets | 0.57 | -0.14 | -0.14 | -0.08 | 0.43 | |
Graham Net | 0.6 | 0.21 | 0.26 | 0.12 | 0.91 | |
Working capital | 113.33M | 96.14M | 42.69M | 35M | 35.18M | |
Tangible asset value | 43.63M | 30.37M | 23.35M | 17.65M | 37.1M | |
Net current asset value | 35.35M | 22.46M | 12.97M | 7.77M | 30.82M | |
Invested capital | 1.12 | 1.43 | 0.7 | 0.85 | 0.04 | |
Average receivables | 1.43M | 1.14M | 933.5K | 1.14M | 1.49M | |
Average payables | 0 | 2.88M | 6.93M | 4.05M | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 639.53 | 403.87 | 0 | 848.41 | 44.94K | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.14 | 0.22 | 0 | 0.11 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 1.46 | -0.4 | -0.32 | -0.22 | 0.54 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
LMNL Frequently Asked Questions
What is Liminal BioSciences Inc. stock symbol ?
Liminal BioSciences Inc. is a CA stock , located in Laval of Qc and trading under the symbol LMNL
What is Liminal BioSciences Inc. stock quote today ?
Liminal BioSciences Inc. stock price is $3.8831 today.
Is Liminal BioSciences Inc. stock public?
Yes, Liminal BioSciences Inc. is a publicly traded company.